The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice-Reference-Cited by-同舟云学术

The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice

Published:2021-01 Issue: Volume:350 Page:577429
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Sun Huanhuan,Wang Jueqiong,Guo Li,Wang Ying,Zhang Jing,Wang Jinli,Quan Moyuan,Li Bin

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference58 articles.

1. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death;Alano;J. Neurosci.,2010

2. Atorvastatin attenuates homocysteine-induced migration of smooth muscle cells through mevalonate pathway involving reactive oxygen species and p38 MAPK;Bao;Clin. Exp. Pharmacol. Physiol.,2015

3. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10 and IL-4 deficient and transgenic mice;Bettelli;J. Immunol.,1998

4. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production andattenuates autoimmune disease;Brereton;J. Immunol.,2009

5. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity;Cavone;Mult. Scler.,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NAD ⁺ affects differentially expressed genes- MBOAT2 - SLC25A21 - SOX6 in experimental autoimmune encephalomyelitis model;International Journal of Neuroscience;2024-02-07

2. The small molecule Erk1/2 signaling pathway inhibitor PD98059 improves DNA repair in an experimental autoimmune encephalomyelitis SJL/J mouse model of multiple sclerosis;Mutation Research/Genetic Toxicology and Environmental Mutagenesis;2023-07

3. Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2022-12

4. Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice;Proceedings of the National Academy of Sciences;2022-10-18

5. Treatment with an Antigen-Specific Dual Microparticle System Reverses Advanced Multiple Sclerosis in Mice;2022-03-27